← FDA DRUG APPROVALS

FDA NDA · NDA207949

CABAZITAXEL

Sponsor: ACCORD HLTHCARE

APPLICATION
NDA207949
TYPE
NDA
ORIGINAL APPROVAL
2021-12-29
LATEST ACTION
2024-10-10
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

CABAZITAXEL · ReferenceDiscontinued
CABAZITAXEL 60MG/3ML (20MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2024-10-10Labeling · Supplement 2 · standardLabelAP
2021-12-29Type 5 - New Formulation or New Manufacturer · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →